New blood test and camera could spot breast cancer earlier, reduce unnecessary biopsies

NCT ID NCT06268405

Recruiting now Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two new ways to find breast cancer in women at high risk: a blood test that looks for tumor DNA and a special mammogram that uses a low-dose radioactive tracer. About 100 women who already need a biopsy will get both tests first. The goal is to see if these tools can help doctors see and understand breast abnormalities better than current methods, which could lead to fewer unnecessary biopsies and less worry.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liquid Biopsy (blood test for tumor DNA) and Positron Emission Mammography (PEM) imaging device
What this could lead to: If successful, these tests could help radiologists spot breast cancer more accurately, potentially reducing unnecessary biopsies and anxiety for high-risk women.
What could go wrong: This is an early-stage study with only 100 participants, so results may not apply to all women. The tests are experimental and may not be more accurate than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.